TO

Tuyen Ong

Chief Executive Officer at Ring Therapeutics, CEO Partner at Flagship Pioneering

Cambridge, Massachusetts

Investor
VC
CEO

Invests in

Stages:

Series B

  • Min Investment:

    $500,000.00

  • Max Investment:

    $15,000,000.00

  • Target Investment:

    $7,000,000.00

Skills

Gene Therapy
Biotechnology
Ophthalmology

Education

Investments

Ring Therapeutics

Series B

Total Funding: $200M

Work Experience

Ring Therapeutics

2020

  • Chief Executive Officer

    2020

Flagship Pioneering

2020

  • CEO partner

    2020

Rectify Pharma

2022

  • Member Board of Directors

    2022

Nevakar Inc.

2017

  • Board of Advisors

    2017

Gemini Therapeutics

2020 - 2022

  • Board of Directors

    2020 - 2022

Biogen

2019 - 2020

  • SVP, Head of Ophthalmology Franchise

    2019 - 2020

NIGHTSTAR THERAPEUTICS

2017 - 2019

  • EVP, Chief Development Officer

    2017 - 2019

    Nightstar Therapeutics (Acquired by Biogen in June 2019)

PTC Therapeutics, Inc.

2014 - 2017

  • Chief Medical Officer

    2014 - 2017

    SVP, Head of Clinical and Research Development (2014-2016)

Bausch + Lomb

2010 - 2014

  • VP, Clinical Development and Operations

    2010 - 2014

    Executive Director, Head of Clinical and Scientific Affairs (2010 -2013)

Pfizer

2005 - 2010

  • Global Clinical Lead

    2005 - 2010